Bcl‐xL as prognostic marker and potential therapeutic target in cholangiocarcinoma
Open Access
- 14 September 2022
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 42 (12) , 2855-2870
Abstract
Intrahepatic, perihilar, and distal cholangiocarcinoma (iCCA, pCCA, dCCA) are highly malignant tumours with increasing mortality rates due to therapy resistances. Among the mechanisms mediating resistance, overexpression of anti‐apoptotic Bcl‐2 proteins (Bcl‐2, Bcl‐xL, Mcl‐1) is particularly important. In this study, we investigated whether antiapoptotic protein patterns are prognostically relevant and potential therapeutic targets in CCA. Bcl‐2 proteins were analysed in a pan‐cancer cohort from the NCT/DKFZ/DKTK MASTER registry trial (n = 1140, CCA n = 72) via RNA‐sequencing and transcriptome‐based protein activity interference revealing high ranks of CCA for Bcl‐xL and Mcl‐1. Expression of Bcl‐xL, Mcl‐1, and Bcl‐2 was assessed in human CCA tissue and cell lines compared with cholangiocytes by immunohistochemistry, immunoblotting, and quantitative‐RT‐PCR. Immunohistochemistry confirmed the upregulation of Bcl‐xL and Mcl‐1 in iCCA tissues. Cell death of CCA cell lines upon treatment with specific small molecule inhibitors of Bcl‐xL (Wehi‐539), of Mcl‐1 (S63845), and Bcl‐2 (ABT‐199), either alone, in combination with each other or together with chemotherapeutics was assessed by flow cytometry. Targeting Bcl‐xL induced cell death and augmented the effect of chemotherapy in CCA cells. Combined inhibition of Bcl‐xL and Mcl‐1 led to a synergistic increase in cell death in CCA cell lines. Correlation between Bcl‐2 protein expression and survival was analysed within three independent patient cohorts from cancer centers in Germany comprising 656 CCA cases indicating a prognostic value of Bcl‐xL in CCA depending on the CCA subtype. Collectively, these observations identify Bcl‐xL as a key protein in cell death resistance of CCA and may pave the way for clinical application.Keywords
Funding Information
- AbbVie
- Deutsche Krebshilfe (70113593, 70113922)
- Deutsche Forschungsgemeinschaft (KO‐5205/3–1, KO‐5205/1–1, 314905040 – SFB/TRR 209)
This publication has 40 references indexed in Scilit:
- Genomic spectra of biliary tract cancerNature Genetics, 2015
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapyNature Reviews Molecular Cell Biology, 2013
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinomaHepatology, 2013
- Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinomaHuman Pathology, 2012
- Up-regulation of microRNA 506 leads to decreased Cl−/HCO3 − anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosisHepatology, 2012
- Prognostic significance of Bcl-xL gene expression in human colorectal cancerActa Histochemica, 2011
- Analysis of apoptosis by propidium iodide staining and flow cytometryNature Protocols, 2006
- Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemiaCancer Biology & Therapy, 2005
- The Bcl2 family: regulators of the cellular life-or-death switchNature Reviews Cancer, 2002
- Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell lineHepatology, 1997